Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MUfDfZRwfG:6aXOgRZN{[Xl? MWm0PEBp M3;oc2ROW09? MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP NEL5cYUzOTV5MkW4PS=>
BAF3 MnLrR5l1d3SxeHnjJGF{e2G7 NEHYPJU1QCCq NXvlV5JCTE2VTx?= Ml75R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP Mof3NlE2PzJ3OEm=
BAF3 NGLvTmxEgXSxdH;4bYMhSXO|YYm= NVLW[ndvPDhiaB?= NXL0ZXNiTE2VTx?= Ml63R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= Mmr5NlE2PzJ3OEm=
Kelly NELsW|dEgXSxdH;4bYMhSXO|YYm= NVjjXXk{TE2VTx?= M{X4OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN NGG3ZWczOTV5MkW4PS=>
SH-SY5Y NYDvO5pSS3m2b4TvfIlkKEG|c3H5 M3XjcWROW09? NX\6b3E6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>? M2q5NVIyPTd{NUi5
SMS-KCN MmnZR5l1d3SxeHnjJGF{e2G7 NVrSfYs2TE2VTx?= NUC2c21kS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? Mke2NlE2PzJ3OEm=
BAF3 NWO5ZoRzS3m2b4TvfIlkKEG|c3H5 MnPROFghcA>? M1nwNWROW09? NX;GS2duS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN M{LIV|IyPTd{NUi5
3T3 MkPqSpVv[3Srb36gRZN{[Xl? NXLLNYlrOSCq MULEUXNQ M{LqR2lvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? M2i1ZVIyQDF{NEG0
3T3-E M3zUVGZ2dmO2aX;uJGF{e2G7 MmO3NUBp NVK4[IM4TE2VTx?= NFHMWpZKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? MmHQNlE5OTJ2MUS=
A549 MXLLbY5ie2ViQYPzZZk> MWKxJIg> MYDEUXNQ NGLiVpNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> MUCyNVgyOjRzNB?=
BAF3-BCL MXPGeY5kfGmxbjDBd5NigQ>? NYLYR3hsOSCq M3PVfWROW09? MoqxTY5pcWKrdHnvckBw\iCDQlygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDFwMUW5JO69VQ>? NFfFfVkzOThzMkSxOC=>
HEK293 MYfGeY5kfGmxbjDBd5NigQ>? M3LZVFEhcA>? MljHSG1UVw>? NXzZT3V7UW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= MV[yNVgyOjRzNB?=
HEK293 NETsdYRHfW6ldHnvckBCe3OjeR?= NHvU[nUyKGh? NWDDemljTE2VTx?= MnXUTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO M1f3WVIyQDF{NEG0
Jurkat MlS1SpVv[3Srb36gRZN{[Xl? NGqxcG8yKGh? M1i1c2ROW09? Ml;GTY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? NH;PbWIzOThzMkSxOC=>
KARPAS299 MnviT4lv[XOnIFHzd4F6 MYCxJIg> MWXEUXNQ M1;6R2lvcGmkaYTpc44hd2ZiQVzLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MVmyNVgyOjRzNB?=
PAE Mn\iSpVv[3Srb36gRZN{[Xl? NUnFT41UOSCq NGXkW5lFVVOR Mki5TY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? NH;QUYQzOThzMkSxOC=>
BAF3 MonWSpVv[3Srb36gRZN{[Xl? MXuyMVMh\A>? MWPEUXNQ MW\Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN MmDGNlM4PDJ{NUK=
KARPAS299 Ml3UR5l1d3SxeHnjJGF{e2G7 NUS0S4U3Oi1|IHS= MmPxSG1UVw>? M3HWR2lEPTB;MD6wOlQzKM7:TR?= NH3Eb4EzOzd2MkK1Ni=>
EBC1 NUPIOYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL3UY44OiCq NVeyeWo2TE2VTx?= MlLSTWM2OD1yLkCyN{DPxE1? NVzKW4k{OjN7OUOzNlg>
HCT116 NXn0[GxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m2SlczKGh? MVjEUXNQ MWnJR|UxRTF2LkiyJO69VQ>? Mm\SNlM6QTN|Mki=
MCF7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTLfpY4OiCq NVz2dG5RTE2VTx?= MYLJR|UxRTlwNUig{txO NWrneXlEOjN7OUOzNlg>
MDA-MB-231 NHTYdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[3NkBp M4fC[2ROW09? MXTJR|UxRTFyLkig{txO MX6yN|k6OzN{OB?=
MKN45 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDXO|IhcA>? MVjEUXNQ NXnHSYRxUUN3ME2wMlAyOyEQvF2= NY[yR2g6OjN7OUOzNlg>
NCI-H441 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLGflc4OiCq MmDiSG1UVw>? NELwNI9KSzVyPUG3MlI2KM7:TR?= M4XXblI{QTl|M{K4
NCI-H661 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp MV;EUXNQ Mki0TWM2OD1zMT60O{DPxE1? M1zab|I{QTl|M{K4
SK-MEL-28 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2iyWFczKGh? NHXUcYhFVVOR NVrIbmFsUUN3ME2xNE46PyEQvF2= NIrQXGwzOzl7M{OyPC=>
SKOV3 M4HaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS3NkBp NYH2[2hJTE2VTx?= MX;JR|UxRTF{Lki1JO69VQ>? Mnn6NlM6QTN|Mki=
SNU5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXLOYs4OiCq M{\HdGROW09? M4TRfmlEPTB;MD6wNVYh|ryP NYTxdYF{OjN7OUOzNlg>
NCI-H2228 NXuxeYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO3NkBp MV\EUXNQ MVfJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN NF\Kb5EzPDR|MkmwPS=>
NCI-H3122 NEP3PXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;SZWE4OiCq NHPhc2ZFVVOR Ml\ZTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> MWWyOFQ{OjlyOR?=
NCI-H3122 M2e3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPzeGtjPzJiaB?= NEHYXZhFVVOR NH:xVWNKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> MW[yOFQ{OjlyOR?=
NCI-H3122 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp MYDEUXNQ MlflTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN M{LZV|I1PDN{OUC5
NIH-3T3 MVLLbY5ie2ViQYPzZZk> NX7YR|kyOSCq M{fBZmROW09? NFnq[3JKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= NFzBWmIzPDR|MkmwPS=>
NIH-3T3 MlSwT4lv[XOnIFHzd4F6 MYixJIg> NEX1UGdFVVOR MkD3TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO MXKyOFQ{OjlyOR?=
NIH-3T3 M{fqR2tqdmG|ZTDBd5NigQ>? NGLNfmUyKGh? NGPjXo5FVVOR M{DQXWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkK2JO69VQ>? MmmwNlQ1OzJ7MEm=
NIH-3T3 MWfLbY5ie2ViQYPzZZk> M{H2OVEhcA>? NHHJVm1FVVOR NELXflhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? MnLzNlQ1OzJ7MEm=
NIH-3T3 NXroO2Y4U2mwYYPlJGF{e2G7 M4eze|EhcA>? M1m5fGROW09? MmHTTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO MX:yOFQ{OjlyOR?=
BAF3 NV7ZeW1FTnWwY4Tpc44hSXO|YYm= MVe3NkBp Ml[wSG1UVw>? NEXaPWlKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO M2O3R|I1PDZ6NkOy
BAF3 NIrlSW5EgXSxdH;4bYMhSXO|YYm= MXS3NkBp NVHKUHQ2TE2VTx?= M2T4bmlEPTB;MD65PEDPxE1? M1vXPFI1PDZ6NkOy
NIH-3T3 Mn7pT4lv[XOnIFHzd4F6 MXuxJIg> NVT2dI0zUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BHOTF5NFygcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6xOlUh|ryP Mmr0NlQ5OTlzMU[=
NIH-3T3 NFjvW4RMcW6jc3WgRZN{[Xl? M{PLVFEhcA>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> MmqzNlQ5OTlzMU[=
NIH-3T3 MmPGT4lv[XOnIFHzd4F6 MVexJIg> MlLKTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO NYW1U3JNOjR6MUmxNVY>
NIH-3T3 M1jpXmtqdmG|ZTDBd5NigQ>? NF\mXW8yKGh? NYDsbWFTUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= M4T2blI1QDF7MUG2
KARPAS299 M1n1W2tqdmG|ZTDBd5NigQ>? MkfNPVAhdWmw M{DaTWROW09? MVPJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> NHLp[JkzPDlyMEe1NC=>
MKN 45 NHXs[pJMcW6jc3WgRZN{[Xl? NYnuT5M1OSCq Mk\ZSG1UVw>? MmrWTY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO M17sTFI1QTByN{Ww
A549 M2XrdmN6fG:2b4jpZ{BCe3OjeR?= NGDqc5g1QCCq MX7EUXNQ NIe3OZhKSzVyIH;mJFQvODh2IN88US=> M1XacVI1QTByOEOw
NCI-H1975 NVLm[VNjS3m2b4TvfIlkKEG|c3H5 MUm0PEBp MWHEUXNQ Mo[wTWM2OCCxZjC3MlU2OSEQvF2= M1XpPFI1QTByOEOw
NCI-H1993 MYnDfZRwfG:6aXOgRZN{[Xl? MX:0PEBp Ml7GSG1UVw>? NGLWdJNKSzVyIH;mJFAvODZzIN88US=> NIPuO2UzPDlyMEizNC=>
NCI-H1993 NE\BflVCeG:2b4Ppd{BCe3OjeR?= MVqxJO69VQ>? M1n6TVI1KGh? NVz0cFN3TE2VTx?= NXeze2hV\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> MlX3NlQ6ODB6M{C=
NIH-3T3 Ml\GR5l1d3SxeHnjJGF{e2G7 NWTwSnFwPDhiaB?= NXXwXYlxTE2VTx?= NUjBdmRZUUN3MDDv[kAxNjN4NDFOwG0> NITEZoIzPDlyMEizNC=>
EBC1 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\IZYE4OiCq MUPEUXNQ NVXOR5JCUUN3MDDv[kAxNjByNkmg{txO Mnz1NlQ6ODB6M{G=
KARPAS299 NHi5emtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrPN|A4OiCq Mk\ISG1UVw>? MlHLTWM2OCCxZjCwMlIh|ryP M1vBUFI1QTByOEOx
NB1 NEfycnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlzLkm4JI5O MXjTRW5ITVJ?
NCI-SNU-5 NILqRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3rUmxKSzVyPUGwOU44PSCwTR?= NXvQSJNQW0GQR1XS
SR MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnEeZJiUUN3ME2xNlYvOzFibl2= M{HPVXNCVkeHUh?=
SF539 NXfzcIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJyND6yOEBvVQ>? M3jNUXNCVkeHUh?=
SU-DHL-1 NIGwW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTOTWM2OD1|M{[uPFIhdk1? NEi0ZZpUSU6JRWK=
SCC-3 M3\vNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfhSnJKSzVyPUO1Ok44PiCwTR?= NGj4[|RUSU6JRWK=
DEL NGr0cVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLaTWM2OD1|NkmuPUBvVQ>? M4DJb3NCVkeHUh?=
CTV-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILUOXpKSzVyPUW5Ok41QCCwTR?= Mn;LV2FPT0WU
EM-2 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[zTWM2OD14MEGuN|Qhdk1? MUDTRW5ITVJ?
MHH-CALL-2 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK3TWM2OD14OEKuOVchdk1? NEfoWIdUSU6JRWK=
KM12 M2jPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDze3RKSzVyPUewOk46KG6P M{Du[HNCVkeHUh?=
KINGS-1 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv5TWM2OD15NEmuO|Uhdk1? NHfxb5BUSU6JRWK=
MEG-01 M2n1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7odG1yUUN3ME24OVcvPjZibl2= M4KyO3NCVkeHUh?=
BV-173 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzTTWM2OD1zLkC1PVk4KM7:TR?= NIjlTYpUSU6JRWK=
LAMA-84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPibZZYUUN3ME2xMlM5Ojh{IN88US=> Ml6zV2FPT0WU
KARPAS-299 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\0WnVKSzVyPUGuOFA5PjFizszN NV[ydFVmW0GQR1XS
K-562 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjxUJpKSzVyPUGuO|IzPjlizszN NEf1WnlUSU6JRWK=
SK-LMS-1 NYOwN4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwN{[4Olch|ryP M1HTOXNCVkeHUh?=
MOLT-16 NIPHZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn5TWM2OD1zLkm1OVc2KM7:TR?= NHLhXHFUSU6JRWK=
CMK MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXUTWM2OD1zLkm2NVU6KM7:TR?= M2f5ZnNCVkeHUh?=
ST486 M1r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\icmlEPTB;Mj60N|A4OyEQvF2= NUjwUZRWW0GQR1XS
CI-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYbGhUUUN3ME2yMlQ6PjV7IN88US=> MXfTRW5ITVJ?
KP-N-RT-BM-1 M1PiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwN{CxNlIh|ryP Mmq5V2FPT0WU
ALL-PO MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LlWGlEPTB;Mz6xPFIxPyEQvF2= NXyyRnVRW0GQR1XS
KS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCRpRvUUN3ME2zMlIyOjJ3IN88US=> MoflV2FPT0WU
Becker NXvsPXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jN[GlEPTB;ND6yN|k{KM7:TR?= MV3TRW5ITVJ?
GDM-1 M2XNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xSGlEPTB;ND6yOFYyPyEQvF2= MXjTRW5ITVJ?
BC-1 NFTOe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jsXWlEPTB;ND60PVI4PyEQvF2= NXTXWlE1W0GQR1XS
NB14 M4nVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G0NWlEPTB;ND64N|UzPCEQvF2= MlX0V2FPT0WU
NOS-1 NYHBUXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVwM{O4O|Qh|ryP NYfL[Xd4W0GQR1XS
MZ1-PC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwOEKxOVEh|ryP NUfPN5pOW0GQR1XS
A498 M2D6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnhTWM2OD14LkC4OFc{KM7:TR?= NYnHc4xxW0GQR1XS
EW-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zTGNKSzVyPU[uN|c4PzNizszN MkO3V2FPT0WU
NALM-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP5PWRKSzVyPU[uOlg{QDdizszN Ml\RV2FPT0WU
EB-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WyOmlEPTB;Nz6wO|I{OyEQvF2= NXXNfJJ7W0GQR1XS
697 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNWWlEPTB;OT6yOFMzQSEQvF2= Ml:5V2FPT0WU
Ramos-2G6-4C10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7H[HVKSzVyPUmuOVk5PDJizszN M37ZRnNCVkeHUh?=
KNS-81-FD NHj1WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRPWlEPTB;OT62PVY2OyEQvF2= MkjmV2FPT0WU
HUTU-80 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[xT21KSzVyPUmuO|Q3PDJizszN M4PnbnNCVkeHUh?=
LS-411N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XoOGlEPTB;MUCuNFU3PyEQvF2= MUPTRW5ITVJ?
RPMI-8402 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzk[nZKSzVyPUGwMlEyPiEQvF2= Mk\XV2FPT0WU
KU812 NEDtUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFyLkK5PVEh|ryP NXzMdZFlW0GQR1XS
EW-1 NYLGV4dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HHcGlEPTB;MUCuOFQzPSEQvF2= M3PPWnNCVkeHUh?=
HC-1 NFX1OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzZcmVKSzVyPUGwMlQ5PDRizszN NXHSfVIyW0GQR1XS
NB69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzMTWM2OD1zMD61NFQ{KM7:TR?= MVPTRW5ITVJ?
MFH-ino NUjzVooyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjidXBKSzVyPUGwMlg{ODNizszN M1HWc3NCVkeHUh?=
CCRF-CEM MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jHdmlEPTB;MUGuOVk4KM7:TR?= MkX1V2FPT0WU
SK-N-DZ NHi5XmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M174U2lEPTB;MUKuNFQ{PiEQvF2= M2jmOXNCVkeHUh?=
NCI-H720 NE\W[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfwTWM2OD1zMj6xO|A2KM7:TR?= NVS2blEyW0GQR1XS
HCC1187 NHrUc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\mO3pKSzVyPUGyMlIxPDFizszN NIG5WHhUSU6JRWK=
IST-SL2 NIHFTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF{LkS4O|Ih|ryP MXvTRW5ITVJ?
KE-37 M4[w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\YS2lEPTB;MUKuO|k3PiEQvF2= MoXlV2FPT0WU
HCC1599 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\udYZIUUN3ME2xNk46ODZ7IN88US=> NHraPVZUSU6JRWK=
A4-Fuk MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{Lkm1PFYh|ryP MV7TRW5ITVJ?
NKM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvKXpVKSzVyPUGzMlI6OjVizszN M1HpenNCVkeHUh?=
BE-13 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjMTWM2OD1zMz63PVg6KM7:TR?= NFfiUW5USU6JRWK=
MV-4-11 NV7tNFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF2LkCzNlQh|ryP NFnPXYpUSU6JRWK=
OPM-2 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37FNmlEPTB;MUSuOFA5PSEQvF2= M4nt[3NCVkeHUh?=
KARPAS-422 NX\zZWZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTkN3FKSzVyPUG0MlUyOjZizszN M4fFZXNCVkeHUh?=
RPMI-8226 NF3vcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPmTWM2OD1zND64PVE2KM7:TR?= M4XOZXNCVkeHUh?=
KARPAS-45 NXTQO4tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH0R3ZKSzVyPUG1Mlc4OTZizszN MVrTRW5ITVJ?
SK-PN-DW NF7ub4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF3Lki2N|Eh|ryP MXPTRW5ITVJ?
LC-2 NVvaUJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF4LkG1NFYh|ryP MYrTRW5ITVJ?
NCI-H1648 NGDl[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP0OVlKSzVyPUG2MlI2PCEQvF2= NFXnXnJUSU6JRWK=
RL95-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ETWM2OD1zNj6zPVc5KM7:TR?= M{XVcHNCVkeHUh?=
KNS-42 NF3yfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO2TWM2OD1zNj63Nlc1KM7:TR?= MkjFV2FPT0WU
RPMI-6666 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXtfmFKSzVyPUG2MlkzOTFizszN NH3nZ3JUSU6JRWK=
SIG-M5 M1fTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNUnpqUUN3ME2xO{4yQTB|IN88US=> NHfsTY9USU6JRWK=
VA-ES-BJ MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TGOmlEPTB;MUeuO|Q2OSEQvF2= NEnyOpBUSU6JRWK=
MONO-MAC-6 NHjlPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHVTWM2OD1zNz65N|EzKM7:TR?= NYfCV3BbW0GQR1XS
LAN-6 M4Dvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf1TWM2OD1zOD63OVU4KM7:TR?= MnrvV2FPT0WU
A388 NFLMZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[3TWM2OD1zOT6zNFU6KM7:TR?= MmPoV2FPT0WU
SK-NEP-1 NIXHWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVflZtUUN3ME2yNE4zOTN{IN88US=> MVzTRW5ITVJ?
TE-10 M3\QVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iwUGlEPTB;MkCuOVIzOSEQvF2= NH7lZVZUSU6JRWK=
HL-60 NWGweHJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJyLkmwPVkh|ryP NY\lXWJSW0GQR1XS
MC116 NXK3dI41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPpTWM2OD1{MT63NlIyKM7:TR?= Mor6V2FPT0WU
SW962 NIjpR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXFUFFKSzVyPUKxMlc6OTVizszN NEDKXHFUSU6JRWK=
NOMO-1 NYrUPHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPreXVKSzVyPUKyMlY2PjRizszN NFrWVG5USU6JRWK=
CTB-1 NYT4[4c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LSbGlEPTB;MkKuPFY4OSEQvF2= MmPUV2FPT0WU
MRK-nu-1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ{LkmwO|Qh|ryP M1LYcnNCVkeHUh?=
GR-ST MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ|Lke2JO69VQ>? MVTTRW5ITVJ?
HH NFTGe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknnTWM2OD1{ND6wNFMh|ryP MYnTRW5ITVJ?
NCI-H1963 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH4VY5QUUN3ME2yOE4xPzh{IN88US=> MmPrV2FPT0WU
QIMR-WIL NVHMb4dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ2Lki3O|Ih|ryP MWDTRW5ITVJ?
CGTH-W-1 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HsWGlEPTB;MkWuNFczOyEQvF2= NIP3WYtUSU6JRWK=
LP-1 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6yV|FSUUN3ME2yOU43PTVzIN88US=> NGnKSndUSU6JRWK=
NCI-H748 NUDQXmRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ4LkWxN|ch|ryP M1LXW3NCVkeHUh?=
PF-382 NFLHPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LuVmlEPTB;MkeuNlIzOyEQvF2= MX3TRW5ITVJ?
ATN-1 NHzuZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnxTWM2OD1{Nz6zO|MzKM7:TR?= NY[wTlM6W0GQR1XS
L-540 M33ESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nDNWlEPTB;MkeuOlQ2QSEQvF2= NX62TW06W0GQR1XS
LXF-289 NIPlNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ5Lke1NVkh|ryP NW\kUnMyW0GQR1XS
LS-513 NH[0NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS0TWM2OD1{OD6xPFA4KM7:TR?= NWfMfpRLW0GQR1XS
NCI-H1581 NEPNd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7L[o4zUUN3ME2zNE4{QTd4IN88US=> NWDnUJJGW0GQR1XS
ES6 NGP4fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNyLk[4PVkh|ryP MYfTRW5ITVJ?
SW982 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNyLki1OlYh|ryP NF\0VJhUSU6JRWK=
DOHH-2 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFiyTmFKSzVyPUOxMlU5QTNizszN NF7C[4tUSU6JRWK=
DB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfuNnBQUUN3ME2zN{46PDNzIN88US=> MnnpV2FPT0WU
MPP-89 M3fWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\GXmlEPTB;M{SuNVc2PiEQvF2= MWrTRW5ITVJ?
LB831-BLC NGTDc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLJTWM2OD1|ND61NVg1KM7:TR?= NXm3XZhtW0GQR1XS
NB5 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\hVnhvUUN3ME2zOE45PTN3IN88US=> MWjTRW5ITVJ?
GB-1 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D0PGlEPTB;M{WuNFQ3QSEQvF2= MXXTRW5ITVJ?
TE-15 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf3cHZHUUN3ME2zOU4zOjN6IN88US=> M3XaVHNCVkeHUh?=
LC4-1 M4PHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ITWM2OD1|NT6zPFQ4KM7:TR?= MV7TRW5ITVJ?
NCI-H747 NV;IeHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN4LkGzOlkh|ryP NGLWSFZUSU6JRWK=
NTERA-S-cl-D1 NEjWcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTN6LkezOFch|ryP MWTTRW5ITVJ?
SK-MM-2 NWX5XVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRyLkGxOFYh|ryP NGGxUIZUSU6JRWK=
TGW MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;vb4c1UUN3ME20NU4xPTZ|IN88US=> NGHEXGxUSU6JRWK=
ONS-76 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjCS2JKSzVyPUSyMlQ5QDNizszN MX7TRW5ITVJ?
CPC-N NIfxT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR{Lkm5O|Eh|ryP M4TGN3NCVkeHUh?=
ES4 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe2TJZKSzVyPUS0MlQyPTNizszN MWLTRW5ITVJ?
Daudi NEPoNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLiTWM2OD12NT6wPFI4KM7:TR?= NGHiS41USU6JRWK=
MOLT-4 NF3yeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HjemlEPTB;NEWuNFg2OyEQvF2= Ml7wV2FPT0WU
HT-144 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fre2lEPTB;NE[uO|I3KM7:TR?= M{PPdHNCVkeHUh?=
SW872 M3XGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrrSWZKSzVyPUS4MlE6OzNizszN MmPKV2FPT0WU
D-283MED NH7VT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm5cIs{UUN3ME20PE4{PTR{IN88US=> NVXLZVV{W0GQR1XS
NCI-H2126 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXWmlEPTB;NEiuPFQ4PiEQvF2= MorzV2FPT0WU
NCI-SNU-16 M3PSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml32TWM2OD12OT6yNVQ{KM7:TR?= NHHoXVJUSU6JRWK=
CESS MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR7LkWwPFgh|ryP MXzTRW5ITVJ?
A101D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELLb45KSzVyPUS5Mlk4OzZizszN NHHXWItUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products4

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID